Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
Why this paper is included
Supporting source evidence:
Additionally, of the 37 peptides, 8 peptides (FETUB, A1AT, ITIH4, FA5, VWF, HGFA, BTD, VTNC) were also significant in the independent validation dataset (Supplementary Table S3-7).A plot of 37 significant peptides (from 27 proteins†) after linear mixed-effect model analysis. † CERU, Ceruloplasmin; FA12, Coagulation factor XII; A1AT, Alpha-1-antitrypsin; ANGT, Angiotensinogen; A2MG, Alpha-2-macroglobulin; APOA1, Apolipoprotein A-I; CRP, C-reactive protein; SAMP, Serum amyloid P-component; CO9, complement C9; VTDB, Vitamin D-binding protein; HEMO, Hemopexin; KLKB1, kallikrein B1; VTNC, Vitronectin; VWF, von Willebrand factor; PROS, Vitamin K-dependent protein S; CBG, Corticosteroid-binding globulin; FA5, Coagulation factor V; VINC, Vinculin; TAGL2, Transgelin-2; BTD, Biotinidase; RAP1B, Ras-related protein Rap-1b; 1433Z, 14-3-3 protein zeta/delta, tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein zeta; HGFA, Hepatocyte growth factor activator; SPP24, Secreted phosphoprotein 24; ITIH4, Inter-alpha-trypsin inhibitor heavy chain H4; FETUB, Fetuin B; TLN1, Talin-1; VPAR, Valproate responder (Alda A score of Valproate ≥ 5); VPANR, Valproate non-responder (Alda A score of Valproate < 5)
Source: Peptides that exhibited a distinct alteration in expression over time. View original paper
Relevance classification does not establish study quality, causation or editorial approval.
Study design Study design awaiting verification.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.
Meta-analysis unclear · Blinding unclear / not reported · Human research reported
How this paper was classified
Automatic source-based classification; awaiting editorial verification. This is not a quality score.
) Considering the potential differences in treatment responses and prognoses among older individuals with BD, the age range of the participants was limited to 18 to 60 yrs.
Source: Methods.
What the study types mean
- Systematic review
- Uses explicit methods to identify, assess and summarise research on a defined question.
- Scoping review
- Maps the extent and characteristics of research on a topic.
- Narrative review
- Discusses existing research; systematic-review methods have not been established by this classification.
- Review / evidence synthesis
- Reviews existing research; the exact review methods need further assessment.
- Randomised controlled trial
- Assigns participants or groups to comparison interventions by chance.
- Non-randomised intervention study
- Examines an intervention without random allocation.
- Cohort study
- Examines exposures and outcomes over time within a defined group.
- Case-control study
- Compares people with an outcome against people without it, examining exposures.
- Cross-sectional study
- Examines a population at a particular point in time.
- Observational study
- Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
- Case report
- Describes an individual case.
- Case series
- Describes a group of individual cases.
- Secondary analysis
- Analyses existing study data; this paper is not automatically another independent trial.
- Laboratory study
- Investigates biological processes in a laboratory setting.
- Qualitative study
- Examines experiences or meanings using qualitative methods.
- Genetic instrumental-variable study
- Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
- Study protocol
- Describes planned methods and is not evidence that the planned study has reported results.
- Multiple reported designs
- More than one design is explicitly reported; examine the supporting methods.
- Study design awaiting verification
- The available source does not establish a sufficiently clear study design.
Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.
Abstracts
Integrated proteomic and genomic analysis to identify predictive biomarkers for valproate response in bipolar disorder: a 6-month follow-up study
Study design awaiting verification · International Journal of Bipolar Disorders · 2024
Original publication title
Integrated proteomic and genomic analysis to identify predictive biomarkers for valproate response in bipolar disorder: a 6-month follow-up study
© The Author(s) 2024
Original publication · Publisher record · CC BY 4.0
Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.
At a glance
Abstract: What background does the paper provide?
Several genetic studies have been undertaken to elucidate the intricate interplay between genetics and drug responses in bipolar disorder (BD). However, there has been notably limited research on biomarkers specifically linked to valproate, with only a few studies investigating integrated proteomic and genomic factors in response to valproate treatment. Therefore, this study aimed to identify biological markers for the therapeutic response to valproate treatment in BD. Patients with BD in remission were assessed only at baseline, whereas those experiencing acute mood episodes were evaluated at three points (baseline, 8 ± 2 weeks, and 6 ± 1 months).
The response to valproate treatment was measured using the Alda scale, with individuals scoring an Alda A score ≥ 5 categorized into the acute-valproate responder (acute-VPAR) group. We analyzed 158 peptides (92 proteins) from peripheral blood samples using multiple reaction monitoring mass spectrometry, and proteomic result-guided candidate gene association analyses, with 1,627 single nucleotide variants (SNVs), were performed using the Korean chip.
Source: BackgroundAbstract: Results
The markers of 37 peptides (27 protein) showed temporal upregulation, indicating possible association with response to valproate treatment. A total of 58 SNVs in 22 genes and 37 SNVs in 16 genes showed nominally significant associations with the Alda A continuous score and the acute-VPAR group, respectively. No SNVs reached the genome-wide significance threshold; however, three SNVs (rs115788299, rs11563197, and rs117669164) in the secreted phosphoprotein 2 gene reached a gene-based false discovery rate-corrected significance threshold with response to valproate treatment.
Significant markers were associated with the pathophysiological processes of bipolar disorders, including the immune response, acute phase reaction, and coagulation cascade. These results suggest that valproate effectively suppresses mechanisms associated with disease progression.
Source: ResultsAbstract: Conclusions
The markers identified in this study could be valuable indicators of the underlying mechanisms associated with response to valproate treatment.
Source: ConclusionsAuthors’ abstract
Background
Several genetic studies have been undertaken to elucidate the intricate interplay between genetics and drug responses in bipolar disorder (BD). However, there has been notably limited research on biomarkers specifically linked to valproate, with only a few studies investigating integrated proteomic and genomic factors in response to valproate treatment. Therefore, this study aimed to identify biological markers for the therapeutic response to valproate treatment in BD. Patients with BD in remission were assessed only at baseline, whereas those experiencing acute mood episodes were evaluated at three points (baseline, 8 ± 2 weeks, and 6 ± 1 months).
The response to valproate treatment was measured using the Alda scale, with individuals scoring an Alda A score ≥ 5 categorized into the acute-valproate responder (acute-VPAR) group. We analyzed 158 peptides (92 proteins) from peripheral blood samples using multiple reaction monitoring mass spectrometry, and proteomic result-guided candidate gene association analyses, with 1,627 single nucleotide variants (SNVs), were performed using the Korean chip.
Results
The markers of 37 peptides (27 protein) showed temporal upregulation, indicating possible association with response to valproate treatment. A total of 58 SNVs in 22 genes and 37 SNVs in 16 genes showed nominally significant associations with the Alda A continuous score and the acute-VPAR group, respectively. No SNVs reached the genome-wide significance threshold; however, three SNVs (rs115788299, rs11563197, and rs117669164) in the secreted phosphoprotein 2 gene reached a gene-based false discovery rate-corrected significance threshold with response to valproate treatment.
Significant markers were associated with the pathophysiological processes of bipolar disorders, including the immune response, acute phase reaction, and coagulation cascade. These results suggest that valproate effectively suppresses mechanisms associated with disease progression.
Conclusions
The markers identified in this study could be valuable indicators of the underlying mechanisms associated with response to valproate treatment.
Supplementary Information
The online version contains supplementary material available at 10.1186/s40345-024-00342-x.
Publication and source details
Original title: Integrated proteomic and genomic analysis to identify predictive biomarkers for valproate response in bipolar disorder: a 6-month follow-up study
Hyunju Lee; Dohyun Han; Kyung Sue Hong; Kyooseob Ha; Hyeyoon Kim; Eun Young Cho; Woojae Myung; Sang Jin Rhee; Jayoun Kim; Tae Hyon Ha; Kang Eun Lee; Hye Won Jung; Yejin Lee; Dongbin Lee; Hyeona Yu; Daseul Lee; Yun Seong Park; Yong Min Ahn; Ji Hyun Baek; Se Hyun Kim
International Journal of Bipolar Disorders · 2024
© The Author(s) 2024https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.http://dx.doi.org/10.13039/501100003725National Research Foundation of KoreaNRF-2019M3C7A1030625NRF-2019M3C7A1030624Ahn Yong Min Baek Ji HyunRepository JATS snapshot; version as supplied
Source retrieved: 2026-11-11T11:30:53.030290+00:00
DOI: 10.1186/s40345-024-00342-x · PMC11101393